Stock Analysis on Net

Amgen Inc. (NASDAQ:AMGN)

$24.99

Economic Value Added (EVA)

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Economic Profit

Amgen Inc., economic profit calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Net operating profit after taxes (NOPAT)1
Cost of capital2
Invested capital3
 
Economic profit4

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 NOPAT. See details »

2 Cost of capital. See details »

3 Invested capital. See details »

4 2024 Calculation
Economic profit = NOPAT – Cost of capital × Invested capital
= × =


The data reveals several noteworthy trends in the financial performance and capital management over the five-year period ending in 2024.

Net Operating Profit After Taxes (NOPAT)
NOPAT exhibited a peak in 2020 at 7,889 million US dollars, followed by a significant decline to 6,412 million in 2021 and a slight further decrease to 6,399 million in 2022. However, there was a recovery in 2023 with NOPAT increasing to 7,802 million, before falling sharply in 2024 to 5,377 million. This pattern indicates volatility in operating profits, with a notable drop in the final reported year.
Cost of Capital
The cost of capital remained relatively stable throughout the period, fluctuating slightly between 8.42% and 8.8%. The lowest recorded cost was in 2023 at 8.42%, and it increased again to 8.58% in 2024. These marginal variations suggest a generally consistent cost structure for financing capital without significant cost pressure changes.
Invested Capital
Invested capital showed moderate growth from 38,776 million US dollars in 2020 to 40,247 million in 2021, with a small decrease in 2022 to 39,722 million. A marked increase occurred in 2023, with invested capital rising sharply to 69,976 million, followed by a slight decrease to 63,169 million in 2024. This surge in invested capital in 2023 could be indicative of significant asset acquisitions, expansions, or investments made during that period.
Economic Profit
The economic profit experienced a consistent decline over the period. Beginning at 4,502 million US dollars in 2020, it dropped to 2,933 million in 2021 and remained almost unchanged at 2,902 million in 2022. The downward trend continued with 1,914 million in 2023, culminating in a slight negative economic profit of -44 million in 2024. This decline, especially turning negative in the final year, suggests that the returns on invested capital have ultimately failed to exceed the cost of capital, raising concerns about value creation in recent times.

In summary, while operating profits showed some recovery mid-period, the sharp increase in invested capital in 2023 did not translate into sustained improvement in economic profit. The cost of capital remained stable, yet economic profit weakened consistently, culminating in a negative figure in the latest year reported. This combination may suggest diminishing returns on new investments or challenges in capital efficiency during the most recent period.


Net Operating Profit after Taxes (NOPAT)

Amgen Inc., NOPAT calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Net income
Deferred income tax expense (benefit)1
Increase (decrease) in allowance for doubtful accounts2
Increase (decrease) in equity equivalents3
Interest expense, net
Interest expense, operating lease liability4
Adjusted interest expense, net
Tax benefit of interest expense, net5
Adjusted interest expense, net, after taxes6
(Gain) loss on marketable securities
Investment income, before taxes
Tax expense (benefit) of investment income7
Investment income, after taxes8
Net operating profit after taxes (NOPAT)

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Elimination of deferred tax expense. See details »

2 Addition of increase (decrease) in allowance for doubtful accounts.

3 Addition of increase (decrease) in equity equivalents to net income.

4 2024 Calculation
Interest expense on capitalized operating leases = Operating lease liability × Discount rate
= × =

5 2024 Calculation
Tax benefit of interest expense, net = Adjusted interest expense, net × Statutory income tax rate
= × 21.00% =

6 Addition of after taxes interest expense to net income.

7 2024 Calculation
Tax expense (benefit) of investment income = Investment income, before tax × Statutory income tax rate
= × 21.00% =

8 Elimination of after taxes investment income.


Net Income
The net income experienced a decline from 7,264 million US dollars in 2020 to 5,893 million US dollars in 2021, representing a notable decrease. It then rebounded moderately to 6,552 million US dollars in 2022, followed by a slight increase to 6,717 million US dollars in 2023. However, net income dropped considerably to 4,090 million US dollars in 2024, the lowest level during the observed period.
Net Operating Profit After Taxes (NOPAT)
NOPAT showed a decreasing trend from 7,889 million US dollars in 2020 to 6,412 million US dollars in 2021. It remained relatively stable in 2022 at 6,399 million US dollars, then rose significantly to 7,802 million US dollars in 2023, reaching the highest point in the series. In 2024, NOPAT dropped sharply to 5,377 million US dollars, marking a substantial decline compared to the previous year.
Overall Trends and Insights
Both net income and NOPAT exhibited volatility throughout the five-year period. After declines in 2021, both metrics partially recovered in 2022 and 2023 before falling steeply in 2024. The divergence between net income and NOPAT in certain years is moderate, with both generally following similar downward and upward moves. The steep drops in 2024 for both indicators may suggest operational or external challenges impacting profitability during that year.

Cash Operating Taxes

Amgen Inc., cash operating taxes calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Provision for income taxes
Less: Deferred income tax expense (benefit)
Add: Tax savings from interest expense, net
Less: Tax imposed on investment income
Cash operating taxes

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).


Provision for Income Taxes
The provision for income taxes initially decreased from 869 million USD in 2020 to 808 million USD in 2021, followed by a further slight decline to 794 million USD in 2022. However, there was a noticeable increase in 2023, reaching 1,138 million USD, before dropping significantly to 519 million USD in 2024. This pattern indicates some volatility, with a peak in 2023 before a steep reduction in the latest year.
Cash Operating Taxes
Cash operating taxes showed a consistent upward trend from 1,493 million USD in 2020 to 1,497 million USD in 2021, then sharply increased to 2,368 million USD in 2022 and further to 2,963 million USD in 2023. However, in 2024, the amount fell to 2,426 million USD, indicating a partial decline after a period of substantial growth. Overall, cash operating taxes more than doubled over the five-year period despite the slight drop in the final year.
General Insights
The data reveals a divergence between provision for income taxes and cash operating taxes. While provision for income taxes fluctuated with a peak in 2023 and a marked decline in 2024, cash operating taxes demonstrated a generally strong upward trajectory with a moderate pullback towards the end. This could suggest variations in tax management strategies, timing differences, or changes in taxable income and cash tax payments over the periods analyzed.

Invested Capital

Amgen Inc., invested capital calculation (financing approach)

US$ in millions

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Current portion of long-term debt
Long-term debt, excluding current portion
Operating lease liability1
Total reported debt & leases
Stockholders’ equity
Net deferred tax (assets) liabilities2
Allowance for doubtful accounts3
Equity equivalents4
Accumulated other comprehensive (income) loss, net of tax5
Adjusted stockholders’ equity
Construction in progress6
Marketable securities7
Invested capital

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Addition of capitalized operating leases.

2 Elimination of deferred taxes from assets and liabilities. See details »

3 Addition of allowance for doubtful accounts receivable.

4 Addition of equity equivalents to stockholders’ equity.

5 Removal of accumulated other comprehensive income.

6 Subtraction of construction in progress.

7 Subtraction of marketable securities.


Total reported debt & leases
The total reported debt and leases show a general upward trend from 2020 to 2024. Beginning at 33,445 million USD in 2020, the figure rises slightly to 33,979 million USD in 2021, followed by a more pronounced increase to 39,640 million USD in 2022. A significant surge occurs in 2023, reaching 65,423 million USD, before slightly declining to 60,879 million USD in 2024. This pattern indicates increased leverage, particularly in 2023, potentially reflecting elevated borrowing or lease obligations during that period.
Stockholders’ equity
Stockholders’ equity demonstrates a declining trend over the analyzed years. Starting at 9,409 million USD in 2020, equity decreases sharply to 6,700 million USD in 2021 and continues downward to 3,661 million USD in 2022. A recovery is observed in 2023 with equity rising to 6,232 million USD, followed by a slight decrease to 5,877 million USD in 2024. Overall, the substantial reduction early in the period suggests diminished net assets, while the partial rebound in 2023 may indicate some restoration of equity value.
Invested capital
Invested capital remains relatively stable from 2020 through 2022, starting at 38,776 million USD in 2020, increasing slightly to 40,247 million USD in 2021, then marginally decreasing to 39,722 million USD in 2022. A significant increase occurs in 2023, with invested capital reaching 69,976 million USD, before declining to 63,169 million USD in 2024. This growth in 2023 aligns with the increase in reported debt and leases, suggesting substantial capital investment or acquisition activities funded by increased liabilities.

Cost of Capital

Amgen Inc., cost of capital calculations

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Borrowings3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2024-12-31).

1 US$ in millions

2 Equity. See details »

3 Borrowings. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Borrowings3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2023-12-31).

1 US$ in millions

2 Equity. See details »

3 Borrowings. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Borrowings3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2022-12-31).

1 US$ in millions

2 Equity. See details »

3 Borrowings. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Borrowings3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2021-12-31).

1 US$ in millions

2 Equity. See details »

3 Borrowings. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Borrowings3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2020-12-31).

1 US$ in millions

2 Equity. See details »

3 Borrowings. See details »

4 Operating lease liability. See details »


Economic Spread Ratio

Amgen Inc., economic spread ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in millions)
Economic profit1
Invested capital2
Performance Ratio
Economic spread ratio3
Benchmarks
Economic Spread Ratio, Competitors4
AbbVie Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Economic profit. See details »

2 Invested capital. See details »

3 2024 Calculation
Economic spread ratio = 100 × Economic profit ÷ Invested capital
= 100 × ÷ =

4 Click competitor name to see calculations.


Economic Profit
The economic profit demonstrates a consistent downward trend over the five-year period. Starting at $4,502 million in 2020, it declines significantly to $2,933 million in 2021 and remains relatively stable in 2022 at $2,902 million. Subsequently, a sharp decrease is observed, with economic profit reducing to $1,914 million in 2023 and eventually turning negative to -$44 million in 2024. This trajectory suggests deteriorating profitability, culminating in a loss in the final year analyzed.
Invested Capital
Invested capital exhibits an overall increasing trend, rising from $38,776 million in 2020 to $69,976 million in 2023, reflecting a substantial increase in capital deployed. However, in 2024, invested capital decreases to $63,169 million, indicating a reduction in the capital base after previous growth. The large increase until 2023 may reflect expansions or asset acquisitions, while the subsequent decrease might signal divestments or asset revaluations.
Economic Spread Ratio
The economic spread ratio reflects the margin between returns and cost of capital. This ratio declines markedly over the period, starting at 11.61% in 2020 and dropping to 7.29% in 2021, with minimal change in 2022 at 7.31%. The decline accelerates thereafter, with the ratio falling sharply to 2.73% in 2023 and becoming slightly negative at -0.07% in 2024. This indicates a diminishing return on invested capital relative to its cost, culminating in a slight value destruction by 2024.
Overall Insights
The data reveals a weakening financial performance characterized by decreasing economic profit and economic spread ratio, signaling reduced efficiency and profitability from invested capital over time. The invested capital expands notably through 2023 before contracting in 2024, suggesting strategic changes or adjustments in asset management. The transition to negative economic profit and economic spread ratio in 2024 raises concerns about value creation and the sustainability of returns relative to capital costs.

Economic Profit Margin

Amgen Inc., economic profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in millions)
Economic profit1
Product sales
Performance Ratio
Economic profit margin2
Benchmarks
Economic Profit Margin, Competitors3
AbbVie Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Economic profit. See details »

2 2024 Calculation
Economic profit margin = 100 × Economic profit ÷ Product sales
= 100 × ÷ =

3 Click competitor name to see calculations.


The financial data over the five-year period indicates several notable trends. Product sales have demonstrated consistent growth, rising from US$24,240 million in 2020 to US$32,026 million in 2024. This steady increase suggests an expanding revenue base and potentially successful market or product strategies behind the sales growth.

Contrastingly, economic profit has exhibited a declining trend. Starting at US$4,502 million in 2020, it decreased to just below zero by 2024, ultimately reaching a negative US$44 million. This erosion in economic profit indicates rising costs or decreased operational efficiency, which might be impairing the company's ability to convert sales growth into economic value.

The economic profit margin mirrors the trend in economic profit, dropping significantly from 18.57% in 2020 to -0.14% in 2024. This shift from a healthy positive margin to a slightly negative one over the period reflects deteriorating profitability relative to sales. Despite the increase in product sales, the diminishing margin highlights challenges in maintaining profitability.

Product Sales
Demonstrated consistent year-over-year growth, increasing approximately 32% over the five-year span.
Economic Profit
Experienced a substantial decline, falling sharply from a strong positive in 2020 to negative territory by 2024, indicative of increasing costs or decreasing efficiency.
Economic Profit Margin
Declined from a robust 18.57% in 2020 to below zero in 2024, signaling deteriorating profitability relative to sales despite revenue growth.

Overall, while sales volume has expanded steadily, profitability metrics suggest underlying issues that may be impacting the company’s economic value creation. The data points to a scenario where rising revenues are not translating proportionally into profit gains, warranting further investigation into cost structures and operational effectiveness.